Section on Infectious Diseases, Department of Internal Medicine, Wake Forest University Health Sciences, Medical Center Boulevard, Winston Salem, NC 27157, USA.
Semin Liver Dis. 2012 May;32(2):167-76. doi: 10.1055/s-0032-1316472. Epub 2012 Jul 3.
Drug-induced liver injury (DILI) associated with antiretroviral treatment has represented an important side effect since the beginning of the HAART era. The lack of standard definition and specific markers makes assessment of DILI very challenging. Several clinical syndromes of DILI have been described over the years; the pathogenic mechanisms are not fully understood. Better knowledge of DILI, identification of high-risk patients using pharmacogenetics, and the availability of antiretroviral agents with improved safety profile have all contributed to decrease the incidence of DILI and to ameliorate its effects. Nevertheless, with an aging human immunodeficiency virus- (HIV-) infected population and increased survival, DILI will probably continue to represent a relevant entity in e HIV therapeutic management.
抗逆转录病毒治疗相关的药物性肝损伤（DILI）自 HAART 时代开始一直是一个重要的副作用。由于缺乏标准定义和特定标志物，DILI 的评估极具挑战性。多年来已经描述了几种 DILI 的临床综合征；其发病机制尚未完全阐明。更好地了解 DILI，使用药物遗传学识别高危患者，以及具有更好安全性特征的抗逆转录病毒药物的可用性，都有助于降低 DILI 的发生率并改善其影响。然而，随着感染人类免疫缺陷病毒（HIV）人群的老龄化和存活率的提高，DILI 可能仍然是 HIV 治疗管理中的一个重要问题。
